Day One Biopharmaceuticals

View in Terminal

Loading quotes...

Forecast

The analysts' average price target is €28.06 (+52.58%). The median is €23.31 (+26.75%).

Buy	6
Hold	6
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Day One Biopharmaceuticals had revenue of €45.78M and net profit of -€18.14M

(EUR)	December 2025	YoY
Revenue	45.78M	-
Gross profit	40.6M	-
Net profit	-18.14M	-
EBITDA	-18.97M	-

Fundamentals

Metric	Value
Market capitalization	€1.99B
Number of shares	103.33M
52-week high/low	€19.30 - €5.05
Dividends	No
Beta	-1.75
P/E ratio	-31.20
PEG ratio	0.60
P/B ratio	5.05
P/S ratio	17.46

Company profile

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.